RECHERCHE :   Cancers du poumon - cancers thoraciques
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
MIRATI 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
Advanced Non-Squamous NSCLC with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy
III
CHUV, HUG
AMGEN 20160323: A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
cancer du poumon à petites cellules
I
CHUV
Amgen 20170543: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation
II
HUG
BEAT-meso/ETOP 13-18: A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
Mésothéliome pleural malin
III
CHUV
BMS CA022-001: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
Tumeurs solides avancées
I, II
CHUV
BMS CA209-73L: A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer
cancer du poumon non à petites cellules localement avancé n’ayant jamais été traité
III
CHUV
CA027-002: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers
Tumeurs solides avancés
I, II
CHUV
BMS CA224-048: A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Tumeurs solides (Mélanome, Cancer du poumon non à petites cellules (NSCLC))
I, II
CHUV
CACZ885T2301: A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
Cancer bronchique non à petites cellules complètement réséqué, stade II à IIIA et IIIB
III
HUG
ETOP 15-19: A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR-mutant NSCLC with acquired resistance
EGFR-mutant NSCLC with acquired resistance
II
HUG
CHESS/ETOP 14-18: A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic nonsmall cell lung cancer
Synchronous oligo-metastatic non small cell lung cancer
II
CHUV, HUG
MeRmaiD-1/D910LC00001: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC
cancer du poumon non à petites cellules
III
CHUV
MK3475-867: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
Medically inoperable NSCLC Stages I and IIA
III
HUG
CHUV-DO-0018-NeoTIL-2019: Pilot Study to Assess the Feasibility, Safety and Efficacy of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes Enriched for Tumor Antigen Specificity (NeoTIL) in Advanced Solid Tumors.
Tumeurs solides
I
CHUV
PT-112-103-PAVE-1: A Phase 1b/2a Dose Escalation and Confirmation Study of PT- 112 in Advanced Solid Tumors in Combination with Avelumab
cancer du poumon non à petites cellules
I
CHUV
SAKK 15/19: Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in ED-SCLC. A multicenter single arm open label phase II trial
extensivestage disease small cell lung cancer
II
HUG
SAKK 17/18: Overcoming Resistance to Immunotherapy combining Gemcitabine with atezolizumab in advanced NSCLC and mesothelioma progressINg under immune-checkpoint inhibitors or gemcitabine. A multicenter, single-arm, open label phase II trial with two cohorts
Advanced NSCLC and mesothelioma progressing under immune-checkpoint inhibitors or gemcitabine
II
HUG
SAKK 19/17 : First line durvalumab in patients with PD-L1 positive, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial
PD-L1 positive advanced Non Small Cell Lung Cancer
II
HUG
SAKK16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) NSCLC. A multicenter phase II trial.
resectable stage III(N2) NSCLC
II
HUG